We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

178 hedge funds and large institutions have $2.08B invested in Mirum Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 76 increasing their positions, 42 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 17

81% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 42

16% more call options, than puts

Call options by funds: $7.97M | Put options by funds: $6.87M

14% more capital invested

Capital invested by funds: $1.82B → $2.08B (+$255M)

11% more funds holding

Funds holding: 160178 (+18)

0% more funds holding in top 10

Funds holding in top 10: 99 (0)

1.51% less ownership

Funds ownership: 113.24%111.73% (-1.5%)

Holders
178
Holders Change
+18
Holders Change %
+11.25%
% of All Funds
2.56%
Holding in Top 10
9
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
35
Increased
76
Reduced
42
Closed
17
Calls
$7.97M
Puts
$6.87M
Net Calls
+$1.1M
Net Calls Change
-$99K
Name Holding Trade Value Shares
Change
Change in
Stake
Nisa Investment Advisors
151
Nisa Investment Advisors
Missouri
$18.4K +$4.47K +112 +31%
PA
152
Parallel Advisors
California
$17.2K +$957 +24 +6%
EWA
153
EverSource Wealth Advisors
Alabama
$14.2K
Jones Financial Companies
154
Jones Financial Companies
Missouri
$13.9K +$14.2K +357 New
National Bank of Canada
155
National Bank of Canada
Quebec, Canada
$13.4K +$12.9K +323 +1,615%
ACM
156
Aster Capital Management
United Arab Emirates
$10.3K +$10.6K +265 New
PNC Financial Services Group
157
PNC Financial Services Group
Pennsylvania
$8.7K +$5.27K +132 +145%
S
158
SignatureFD
Georgia
$8.62K +$1.64K +41 +23%
MA
159
MCF Advisors
Kentucky
$7.92K +$8.1K +203 New
HWM
160
HighMark Wealth Management
Minnesota
$7.02K -$3.39K -85 -32%
Daiwa Securities Group
161
Daiwa Securities Group
Japan
$7K +$1.6K +40 +27%
A
162
AlphaQuest
New York
$6.67K -$38.7K -971 -85%
HMS
163
Hanseatic Management Services
New Mexico
$6.16K +$6.3K +158 New
Carson Wealth (CWM LLC)
164
Carson Wealth (CWM LLC)
Nebraska
$5K +$2.95K +74 +154%
LC
165
Lindbrook Capital
California
$3.82K +$1.28K +32 +48%
PFA
166
Pathway Financial Advisers
Indiana
$3.39K
TWC
167
TD Waterhouse Canada
Ontario, Canada
$3.13K +$3.11K +78 New
MPWT
168
MassMutual Private Wealth & Trust
Connecticut
$3.08K +$199 +5 +7%
GI
169
GAMMA Investing
California
$2.3K +$1.96K +49 +490%
RIL
170
Rothschild Investment LLC
Illinois
$1.75K +$1.2K +30 +200%
SCM
171
Sterling Capital Management
North Carolina
$1.56K +$1.6K +40 New
PFC
172
Phocas Financial Corp
California
$1.48K -$898K -22,510 -37%
C
173
Covestor
United Kingdom
$1K -$319 -8 -35%
Bessemer Group
174
Bessemer Group
New Jersey
$1K +$1.2K +30 New
CPA
175
Capital Performance Advisors
California
$624 +$638 +16 New

MIRM Hedge Fund Activity: Q3 2024 in Review

178 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2024, worth a combined $2.08B — up 14% from $1.82B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new MIRM positions and 17 closed out — a net gain of 18 holders — while 76 added to existing stakes and 42 trimmed.

The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $29.6M. The largest seller was BVF Inc, cutting an estimated $51.6M.

  • 178 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2024, up from 160 in Q2 2024.
  • Funds reported $2.08B of Mirum Pharmaceuticals stock for Q3 2024, up 14% quarter-over-quarter.
  • 35 funds opened new Mirum Pharmaceuticals positions in Q3 2024 and 17 closed out, a net change of +18 holders.
  • The largest Mirum Pharmaceuticals buyer in Q3 2024 was Lord, Abbett & Co, an estimated $29.6M added.
  • The largest Mirum Pharmaceuticals seller in Q3 2024 was BVF Inc, an estimated $51.6M sold.

Based on aggregated 13F filings for Q3 2024.